
Marksans Pharma Limited has informed the Exchange regarding a press release dated September 23, 2025, titled "Marksans Pharma Ltd's subsidiary Relonchem Limited in UK received marketing authorisation for its products from UK MHRA.".
Filed with NSE ·

Marksans Pharma Limited has informed the Exchange regarding a press release dated September 23, 2025, titled "Marksans Pharma Ltd's subsidiary Relonchem Limited in UK received marketing authorisation for its products from UK MHRA.".
6ix hasn’t read this filing yet.
Marksans Pharma Limited on 6ix
Follow Marksans Pharma into a list and get an email when it puts out news.
Follow Marksans Pharma